Cart is empty A recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center, demonstrated that a new chemotherapy combination—trifluridine/tipiracil (FTD/TPI) and oxaliplatin—is well tolerated and has activity among patients with esophageal cancer.
Leave A Comment